Gosset Iuvantium General Information
Iuvantium is an Oxford-based biotech startup founded in late 2022, developing a novel inorganic adjuvant platform to precisely engineer immunogenicity. The company targets antimicrobial resistance by enabling next-generation vaccines and therapeutics through a disease and antigen agnostic approach. It has secured competitive funding from iiCON/Innovate UK to accelerate preclinical development, with animal studies as the next step. Early partnerships have been established with universities and hospitals; pharma collaborations are planned. The company’s technology aims to induce specific immune responses such as Th17 for infectious disease defense, with future applications in cancer therapy also envisioned.
Contact Information
United Kingdom
Drug Pipeline
No pipeline data available
Key Partnerships
Research partnerships with universities and hospitals established; pharma/biotech partnerships planned but not yet announced., Funding partnership/grant from iiCON via Innovate UK.
Iuvantium Funding
No funding data available